Lantheus sees 2023 revenue $1.295B-$1.297B, consensus $1.27B

Expected worldwide revenue for the full year 2023, excluding the RELISTOR sales milestone of $15 million, represents an increase of approximately 37% over the prior year period; PYLARIFY revenue for the full year 2023 is expected to be in the range of $851 – 853 million, pending final partner reconciliation, compared with $527.4 million for full year 2022, which represents an increase of approximately 61 – 62%; and DEFINITY revenue for the full year 2023 is expected to be approximately $279 million, compared with $245 million for full year 2022, which represents an increase of approximately 14%. “Lantheus has consistently exemplified our strong commitment to excellence and has been at the forefront in the ongoing renaissance in the radiopharmaceutical industry,” stated Mary Anne Heino, Chief Executive Officer of Lantheus. “Over the course of the past year, Lantheus has impacted the lives of more than six million patients and their families. Our efforts have resulted in record revenues and a period of exceptional achievement. As we head into 2024, Lantheus is well positioned for growth and to deliver sustained shareholder value, driven by our radiopharmaceutical platform and supported by the dedicated efforts of the Lantheus team to Find, Fight and Follow disease to deliver better patient outcomes.”